U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Wednesday.The company reported quarterly earnings of 81 cents per share, which beat the analyst consensus estimate of 77 cents per share. The company reported quarterly sales of $14.438 billion, which beat the analyst consensus estimate of $13.943 billion.HP shares dipped 5.2% to $17.25 in pre-market trading.Here are some other stocks moving lower in pre-market trading.Photo via Shutterstock ...

分组1 - Alphatec reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of $0.04 per share, compared to a loss of $0.23 per share a year ago, representing an earnings surprise of +50.00% [1] - The company posted revenues of $212.93 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.13%, and this is an increase from year-ago revenues of $176.79 million [2] - Alphatec has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has underperformed, losing about 37.5% since the beginning of the year, while the S&P 500 has declined by only 0.1% [3] - The current consensus EPS estimate for the coming quarter is $0.01 on revenues of $201.28 million, and for the current fiscal year, it is $0.24 on revenues of $889.32 million [7] - The Medical - Instruments industry, to which Alphatec belongs, is currently in the top 29% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Management also addressed an apparent shift in quarterly patterns. Koning said momentum in deformity contributed to stronger volumes in the second and third quarters of 2025, which reduced the typical sequential jump in the fourth quarter. “What initially looks like deceleration is masking underlying momentum,” he said.In the U.S., same-store sales in established territories grew 20% year-over-year. EOS revenue grew 14% year-over-year to $23 million .Surgical revenue grew 21% year-over-year and 7% sequentia ...

Alphatec (NasdaqGS:ATEC) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsBen Haynor - Managing Director of Medical Technology ResearchPat Miles - CEOTodd Koning - CFOConference Call ParticipantsMatthew Blackman - Research AnalystOperatorGood afternoon, everyone, and welcome to the webcast of ATEC's fourth quarter and full year 2025 financial results. We would like to remind everyone that participants on the call will make forward-looking statements. These statements are based on curr ...

Alphatec (NasdaqGS:ATEC) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsBen Haynor - Managing Director of Medical Technology ResearchPat Miles - CEOTodd Koning - CFOConference Call ParticipantsMatthew Blackman - Research AnalystOperatorGood afternoon, everyone, and welcome to the webcast of ATEC's fourth quarter and full year 2025 financial results. We would like to remind everyone that participants on the call will make forward-looking statements. These statements are based on curr ...

Alphatec (NasdaqGS:ATEC) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker2Good afternoon, everyone, and welcome to the webcast of ATEC's fourth quarter and full year 2025 financial results. We would like to remind everyone that participants on the call will make forward-looking statements. These statements are based on current expectations and are subject to uncertainties that could cause actual results to differ materially. These uncertainties are detailed in documents filed regularly with the S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 000-52024 ALPHATEC HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 20-2463898 (State or Other Jurisdiction o ...

Q4 2025 FINANCIAL RESULTS PAT MILES, CHAIRMAN & CEO | TODD KNING, EVP & CFO | FEBRUARY 24, 2026 FORWARD-LOOKING STATEMENTS This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking stateme ...

Core Viewpoint - Alphatec Holdings Inc. is identified as a high short interest stock with significant upside potential, driven by its growth strategies and recent partnerships [1]. Group 1: Financial Outlook - TD Cowen has lowered its price target for Alphatec from $27 to $20 while maintaining a Buy rating, indicating a belief that the market has not fully recognized the company's growth potential [1]. - Alphatec's revenue outlook for 2026 is projected to reach $890 million, suggesting strong future growth [1]. Group 2: Strategic Partnerships - On January 12, Alphatec entered a partnership with Theradaptive, acquiring exclusive US commercial rights to market OsteoAdapt, a new osteoinductive bone graft for spinal fusion [2]. - The partnership is structured to provide long-term value through upfront and milestone payments, along with perpetual royalties, aiming to disrupt the $10 billion US spine biologics market [3]. Group 3: Company Overview - Alphatec Holdings Inc. specializes in medical technology for the surgical treatment of spinal disorders, operating both in the US and internationally [4].

Group 1 - The article does not provide any relevant content regarding the company or industry [1]